Archer Advances Quantum Qubit and Biochip Prototypes Amid Strong Cash Position

• Progress on quantum qubit device and readout
• Alpha-prototype blood potassium Biochip meets clinical accuracy
• First phase completion of quantum machine learning for fraud detection
• Scaling carbon material growth for wafer-scale device fabrication
• Strong cash balance of $10.3 million with no debt

Quantum Qubit Device Development Progresses

Archer Materials (ASX:AXE) is steadily advancing its quantum computing ambitions, focusing on building and demonstrating a qubit device essential for future quantum computers. The company is refining nanometre-sized single electron transistors fabricated from its proprietary carbon materials, including graphene and nanoonions, to isolate and probe electron spin states via magnetic fields. This spin readout is critical to qubit operation, and in-house measurements have accelerated iterative design and fabrication cycles.

The team is also scaling carbon material growth to wafer scale, enabling more robust device fabrication and testing. These efforts are part of Archer's roadmap to produce a demonstrator qubit, with ongoing commercial discussions and collaboration with partners to improve quantum technology capabilities. This technical momentum builds on earlier milestones such as improved qubit readout and device control reported in previous quarters, including the quantum carbon films progress.

Biochip Alpha Prototype Achieves Clinical Standard Accuracy

In medical diagnostics, Archer has delivered an alpha-prototype of its blood potassium Biochip, designed to monitor life-threatening potassium imbalances in patients with kidney, cardiovascular, and diabetic conditions. The prototype demonstrated potassium measurement accuracy within ±0.3 mM, meeting Clinical Laboratory Improvement Amendments (CLIA) standards for pathology lab equivalence. This milestone confirms the device’s operational stability and clinical relevance, combining the Biochip, test cartridge, and readout electronics into a functional unit.

The alpha-prototype serves as a foundation for the beta-prototype planned later this year, which will support clinical trials and underpin licensing discussions with major MedTech companies. Archer is also expanding potential applications beyond potassium sensing, conducting feasibility studies for other analytes and market analysis for next-generation diagnostics. This development follows prior progress in silicon-based Biochip accuracy and manufacturing collaborations, including the Biochip beta prototype stage reached earlier in 2026.

Quantum Machine Learning Model Advances Fraud Detection

Archer completed the first phase of its Quantum Machine Learning (QML) project aimed at improving fraud detection in financial transactions. Utilizing a publicly available dataset of over 280,000 bank transactions, including confirmed fraud cases, the team applied data reduction techniques to accommodate current quantum hardware limitations. This approach allows benchmarking against classical machine learning methods.

The next phase involves QML simulations and prototype development, with a full QML prototype expected by the end of 2026. This initiative highlights the potential for quantum-enhanced software to deliver faster and more efficient data analysis, complementing Archer’s hardware-focused quantum efforts. The project builds on Archer’s collaboration with CSIRO and earlier quantum machine learning research combating financial fraud.

Collaborations and Financial Health Support Growth

Archer is also progressing its partnership with Emergence Quantum to explore graphene-based quantum device applications across multiple domains. Meanwhile, collaboration with the Swiss Federal Technology Institute of Lausanne (EPFL) continues to advance carbon film growth and testing, aiming to develop quantum magnetometers with potential applications in medicine and navigation.

Financially, Archer maintains a strong cash position of $10.3 million with no debt, providing a solid runway for ongoing R&D and commercialisation activities. Operating cash flows remain modestly positive, supported by government grants and efficient cost management. Executive and non-executive director fees accounted for $154,000 of quarterly cash outflows, reflecting disciplined corporate governance.

Bottom Line?

Archer’s simultaneous progress on quantum computing and medical diagnostics prototypes, backed by a healthy cash reserve, positions it well for critical beta-prototype milestones and commercial partnerships in the coming months.

Questions in the middle?

• How will Archer’s beta-prototype Biochip perform in upcoming clinical trials and regulatory reviews?
• What commercial partnerships might emerge from the graphene-based quantum device collaboration with Emergence Quantum?
• Can Archer’s quantum machine learning prototype deliver meaningful improvements over classical fraud detection methods?